Aclaris Therapeutics (ACRS) Competitors $1.57 +0.06 (+3.97%) Closing price 06/11/2025 04:00 PM EasternExtended Trading$1.57 0.00 (0.00%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ACRS vs. SANA, TRVI, BCAX, AUTL, EOLS, PHAT, CDXC, STOK, UPB, and TSHAShould you be buying Aclaris Therapeutics stock or one of its competitors? The main competitors of Aclaris Therapeutics include Sana Biotechnology (SANA), Trevi Therapeutics (TRVI), Bicara Therapeutics (BCAX), Autolus Therapeutics (AUTL), Evolus (EOLS), Phathom Pharmaceuticals (PHAT), ChromaDex (CDXC), Stoke Therapeutics (STOK), Upstream Bio (UPB), and Taysha Gene Therapies (TSHA). These companies are all part of the "pharmaceutical products" industry. Aclaris Therapeutics vs. Its Competitors Sana Biotechnology Trevi Therapeutics Bicara Therapeutics Autolus Therapeutics Evolus Phathom Pharmaceuticals ChromaDex Stoke Therapeutics Upstream Bio Taysha Gene Therapies Aclaris Therapeutics (NASDAQ:ACRS) and Sana Biotechnology (NASDAQ:SANA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, profitability, community ranking, dividends and analyst recommendations. Which has better earnings & valuation, ACRS or SANA? Aclaris Therapeutics has higher revenue and earnings than Sana Biotechnology. Sana Biotechnology is trading at a lower price-to-earnings ratio than Aclaris Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAclaris Therapeutics$17.78M9.56-$88.48M-$1.39-1.13Sana BiotechnologyN/AN/A-$283.26M-$0.88-3.07 Is ACRS or SANA more profitable? Sana Biotechnology has a net margin of 0.00% compared to Aclaris Therapeutics' net margin of -136.65%. Aclaris Therapeutics' return on equity of -40.26% beat Sana Biotechnology's return on equity.Company Net Margins Return on Equity Return on Assets Aclaris Therapeutics-136.65% -40.26% -31.71% Sana Biotechnology N/A -84.22%-44.97% Do analysts recommend ACRS or SANA? Aclaris Therapeutics currently has a consensus price target of $9.71, indicating a potential upside of 518.74%. Sana Biotechnology has a consensus price target of $10.80, indicating a potential upside of 300.00%. Given Aclaris Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Aclaris Therapeutics is more favorable than Sana Biotechnology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aclaris Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11Sana Biotechnology 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86 Do institutionals and insiders believe in ACRS or SANA? 98.3% of Aclaris Therapeutics shares are held by institutional investors. Comparatively, 88.2% of Sana Biotechnology shares are held by institutional investors. 6.4% of Aclaris Therapeutics shares are held by company insiders. Comparatively, 30.1% of Sana Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has more volatility & risk, ACRS or SANA? Aclaris Therapeutics has a beta of 0.41, meaning that its stock price is 59% less volatile than the S&P 500. Comparatively, Sana Biotechnology has a beta of 1.78, meaning that its stock price is 78% more volatile than the S&P 500. Does the media prefer ACRS or SANA? In the previous week, Sana Biotechnology had 3 more articles in the media than Aclaris Therapeutics. MarketBeat recorded 6 mentions for Sana Biotechnology and 3 mentions for Aclaris Therapeutics. Aclaris Therapeutics' average media sentiment score of 1.78 beat Sana Biotechnology's score of 1.03 indicating that Aclaris Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aclaris Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Sana Biotechnology 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community prefer ACRS or SANA? Aclaris Therapeutics received 367 more outperform votes than Sana Biotechnology when rated by MarketBeat users. Likewise, 66.84% of users gave Aclaris Therapeutics an outperform vote while only 63.16% of users gave Sana Biotechnology an outperform vote. CompanyUnderperformOutperformAclaris TherapeuticsOutperform Votes39166.84% Underperform Votes19433.16% Sana BiotechnologyOutperform Votes2463.16% Underperform Votes1436.84% SummaryAclaris Therapeutics beats Sana Biotechnology on 12 of the 18 factors compared between the two stocks. Get Aclaris Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACRS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ACRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACRS vs. The Competition Export to ExcelMetricAclaris TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$163.50M$6.85B$5.57B$8.62BDividend YieldN/A2.56%5.28%4.18%P/E Ratio-3.028.7827.1720.06Price / Sales9.56255.64410.88157.10Price / CashN/A65.8538.2534.64Price / Book0.716.557.094.70Net Income-$88.48M$143.93M$3.23B$247.88M7 Day Performance0.64%3.97%2.91%2.66%1 Month Performance25.60%11.32%9.09%6.40%1 Year Performance36.52%4.20%31.75%14.07% Aclaris Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACRSAclaris Therapeutics2.6962 of 5 stars$1.57+4.0%$9.71+518.7%+40.2%$163.50M$17.78M-3.02100Positive NewsSANASana Biotechnology2.4752 of 5 stars$2.83-0.4%$10.80+281.6%-60.8%$640.36MN/A-2.02380Positive NewsTRVITrevi Therapeutics3.5 of 5 stars$6.41-9.2%$18.63+190.6%+140.4%$640.31MN/A-14.5720BCAXBicara Therapeutics2.3353 of 5 stars$11.48-0.2%$31.86+177.5%N/A$626.07MN/A0.0032Positive NewsAnalyst RevisionAUTLAutolus Therapeutics2.6554 of 5 stars$2.35+0.4%$9.32+296.6%-48.0%$625.43M$9.01M-1.94330EOLSEvolus4.115 of 5 stars$9.65-3.9%$23.75+146.1%-11.6%$622.19M$275.46M-10.60170Positive NewsInsider TradeGap UpHigh Trading VolumePHATPhathom Pharmaceuticals4.0864 of 5 stars$8.83-1.0%$17.50+98.2%-18.0%$616.46M$81.86M-1.55110Analyst ForecastOptions VolumeHigh Trading VolumeCDXCChromaDex2.6069 of 5 starsN/A$9.03+∞N/A$611.50M$99.60M787.29120STOKStoke Therapeutics3.8079 of 5 stars$11.13-0.1%$23.20+108.4%-27.4%$607.67M$190.91M-5.30100Analyst RevisionUPBUpstream Bio1.8962 of 5 stars$11.29+0.2%$56.50+400.4%N/A$607.33M$2.30M0.0038TSHATaysha Gene Therapies3.8464 of 5 stars$2.80-1.4%$7.57+170.4%-28.8%$601.05M$7.22M4.44180Analyst ForecastAnalyst Revision Related Companies and Tools Related Companies Sana Biotechnology Competitors Trevi Therapeutics Competitors Bicara Therapeutics Competitors Autolus Therapeutics Competitors Evolus Competitors Phathom Pharmaceuticals Competitors ChromaDex Competitors Stoke Therapeutics Competitors Upstream Bio Competitors Taysha Gene Therapies Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ACRS) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump Makes Major Crypto AnnouncementPay close attention to what I'm about to share… Most investors think Trump's pro-crypto policies will lift ...Crypto 101 Media | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredMarch 16th -- America’s most important day?50-Year Legend: Here's The Day Stocks Likely Crash Legendary quant analyst Marc Chaikin says in 50 years on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aclaris Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aclaris Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ACRS Stock Free ACRS Stock Alerts